Sichuan Kelun-Biotech Biopharmaceutical Full Year 2023 Earnings: Misses Expectations

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.54b (up 92% from FY 2022).
• Net loss: CN¥522.2m (loss narrowed by 4.7% from FY 2022).
• CN¥2.84 loss per share (improved from CN¥5.74 loss in FY 2022).

6990 Products In Clinical Trials

• Phase I: 32.
• Phase II: 7.

6990 Post-Clinical Trial Products

• Pre-registration: 4.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sichuan Kelun-Biotech Biopharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 89%.

The primary driver behind last 12 months revenue was the The United States of America segment contributing a total revenue of CN¥1.53b (99% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to CN¥1.03b (79% of total expenses). Explore how 6990's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 6.4% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Sichuan Kelun-Biotech Biopharmaceutical that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.